Back to Search
Start Over
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
- Source :
-
Future oncology (London, England) [Future Oncol] 2022 Aug; Vol. 18 (26), pp. 2967-2978. Date of Electronic Publication: 2022 Jul 26. - Publication Year :
- 2022
-
Abstract
- Over the past 20 years, the management of gastrointestinal stromal tumors has acted as an important model in the advancement of molecularly targeted therapies for solid tumors. The success of imatinib has established it as a lasting therapy in the management of early-stage and advanced disease in the first-line setting. Imatinib resistance inevitably develops, resulting in the need for further lines of therapy. Ripretinib is an orally administered switch-control tyrosine kinase inhibitor, specifically developed to target both primary and secondary KIT and PDGFRα resistance mutations. Herein, the authors discuss the molecular rationale, the preclinical evidence and the clinical use of ripretinib in the treatment of gastrointestinal stromal tumors in the advanced stages of disease.
- Subjects :
- Drug Approval
Drug Resistance, Neoplasm genetics
Humans
Imatinib Mesylate pharmacology
Imatinib Mesylate therapeutic use
Mutation
Naphthyridines
Protein Kinase Inhibitors pharmacology
Protein Kinase Inhibitors therapeutic use
Proto-Oncogene Proteins c-kit genetics
Urea analogs & derivatives
Antineoplastic Agents pharmacology
Antineoplastic Agents therapeutic use
Gastrointestinal Neoplasms drug therapy
Gastrointestinal Neoplasms genetics
Gastrointestinal Neoplasms pathology
Gastrointestinal Stromal Tumors drug therapy
Gastrointestinal Stromal Tumors genetics
Gastrointestinal Stromal Tumors pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8301
- Volume :
- 18
- Issue :
- 26
- Database :
- MEDLINE
- Journal :
- Future oncology (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 35880452
- Full Text :
- https://doi.org/10.2217/fon-2022-0226